These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 32203842)

  • 1. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
    Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
    Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
    Nauseef JT; Villamar DM; Lebenthal J; Vlachostergios PJ; Tagawa ST
    Expert Opin Pharmacother; 2020 Jun; 21(8):863-870. PubMed ID: 32124650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
    Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
    Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
    Morales-Barrera R; Suárez C; de Castro AM; Racca F; Valverde C; Maldonado X; Bastaros JM; Morote J; Carles J
    Cancer Treat Rev; 2016 Nov; 50():208-216. PubMed ID: 27743530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibition of fibroblast growth factor receptors in cancer.
    Liang G; Chen G; Wei X; Zhao Y; Li X
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
    Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
    Marseglia G; Lodola A; Mor M; Castelli R
    Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of metastatic bladder cancer.
    Nadal R; Bellmunt J
    Cancer Treat Rev; 2019 Jun; 76():10-21. PubMed ID: 31030123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FGFR in bladder cancer: ready for clinical practice?
    De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
    Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
    [No Abstract]   [Full Text] [Related]  

  • 20. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
    Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.